Although ICIs were expected to exhibit great potential in the immunotherapy of CESC patients, the clinical outcomes and prognosis were far from satisfactory, as only less than 20% patients achieved a partial or complete response where most had a PD-L1-positive tumors (Frenel et al., 2017; Chung et al., 2019). The gene discussed is CD274; the disease is cervical squamous cell carcinoma.